Sign inJoin waitlistJoin the waitlist

Kipp Weiskopf

Head of Antibody Therapeutics and Biologics, BIDMC Cancer Research Institute · Beth Israel Deaconess Medical Center

Credentials: · · · ·

History

BIDMC Cancer Research Institute Division · Beth Israel Deaconess Medical Center
Present

Hematology and Medical Oncology
Mass General Brigham
2021–2024
Dana-Farber Cancer Institute
2019–2021
Internal Medicine
Brigham and Women's Hospital
2016–2019
Stanford University School of Medicine
2012–2016

Research

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Proceedings of the National Academy of Sciences of the United States of America · 2012 · 1,402 citations
Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47
Science Translational Medicine · 2010 · 625 citations
Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response
Proceedings of the National Academy of Sciences of the United States of America · 2013 · 562 citations

Holbrook Kohrt
6 papers
Peter Schnorr
6 papers
Ravi Majeti
6 papers
Ronald Levy
6 papers
Dimitrios Colevas
4 papers
MC
Mark Chao
4 papers · 2 as a resident
NR
Nan Ring
4 papers · 3 as a resident
Wen-Kai Weng
4 papers
AB
Amira Barkal
3 papers
Asaf Maoz
3 papers · 2 as a fellow
Ash Alizadeh
3 papers · 1 as a fellow
Benson George
3 papers

Grants

KRAS Inhibitors Prime Cancer Cells for Macrophage-Mediated Destruction
National Cancer Institute · R01
Contact PI · $1.7M · Beth Israel Deaconess Medical Center
2023–2028
EVOLVING HIGH AFFINITY SIRPa MUTANTS TO STIMULATE PHAGOCYTOSIS OF TUMOR CELLS
National Cancer Institute · F30
Contact PI · $142.1K · Stanford University
2012–2015